-
4 March, 2026
Obesity and heart failure: what changes with the new European indication for tirzepatide
March 4, World Obesity Day, is an opportunity to remember that obesity is not an aesthetic issue but a complex chronic disease with a direct impact on metabolic and cardiovascular health. In this context, the recent extension of the European indication for tirzepatide —the active ingredient of Mounjaro— in patients with obesity and heart failure opens a new therapeutic scenario.
To understand what this change really means, we spoke with Dr. Jesús Blanco, endocrinologist at barnaclínic+ and the Hospital Clínic of Barcelona, and with Dr. Pedro Caravaca, cardiologist specializing in heart failure at the Hospital Clínic of Barcelona. Both agree on a key point: obesity must now be addressed as a chronic inflammatory disease with systemic consequences, especially for the heart.
